CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 162 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2021. The put-call ratio across all filers is 0.67 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,007,160 | +3.5% | 145,609 | +27.6% | 0.01% | +7.7% |
| Q2 2023 | $3,872,431 | -4.4% | 114,130 | +1.4% | 0.01% | -7.1% |
| Q1 2023 | $4,049,909 | -19.5% | 112,560 | -0.2% | 0.01% | -22.2% |
| Q4 2022 | $5,028,343 | -43.8% | 112,819 | -64.6% | 0.02% | 0.0% |
| Q3 2022 | $8,951,646 | +29.9% | 318,438 | +24.6% | 0.02% | +38.5% |
| Q2 2022 | $6,891,919 | -34.7% | 255,632 | -17.5% | 0.01% | -13.3% |
| Q1 2022 | $10,553,677 | +71.9% | 309,846 | +95.0% | 0.02% | -6.2% |
| Q4 2021 | $6,141,000 | -30.2% | 158,922 | -2.5% | 0.02% | -36.0% |
| Q3 2021 | $8,800,000 | -42.5% | 162,983 | -64.4% | 0.02% | +13.6% |
| Q2 2021 | $15,312,000 | +149.6% | 457,902 | +53.8% | 0.02% | +15.8% |
| Q1 2021 | $6,134,000 | +3233.7% | 297,783 | +2736.0% | 0.02% | +1800.0% |
| Q4 2020 | $184,000 | – | 10,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 1,017,524 | $20,961,000 | 7.56% |
| Octagon Capital Advisors LP | 561,398 | $11,565,000 | 4.36% |
| COMMODORE CAPITAL LP | 369,951 | $7,621,000 | 3.04% |
| Opaleye Management Inc. | 985,000 | $20,291,000 | 2.98% |
| VR Adviser, LLC | 1,240,610 | $25,557,000 | 2.77% |
| TSP Capital Management Group, LLC | 359,229 | $7,400,000 | 2.61% |
| RTW INVESTMENTS, LP | 3,908,947 | $80,524,000 | 1.26% |
| Ghost Tree Capital, LLC | 250,000 | $5,150,000 | 1.21% |
| Tri Locum Partners LP | 196,672 | $4,051,000 | 1.00% |
| Redmile Group, LLC | 3,387,788 | $69,788,000 | 0.98% |